SCHEMBL7744358

SCHEMBL7744358

N=C(N)c1ccc(OC(=O)c2ccccc2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.74
PRSS1 P07477 6/20 0.57
TMPRSS15 P98073 4/20 0.57
F2 P00734 3/20 0.57
PKM P14618 2/20 0.57
F10 P00742 1/20 0.57
F12 P00748 1/20 0.57
F7 P08709 1/20 0.57
F3 P13726 1/20 0.57
KMT2A Q03164 5/20 0.57
MEN1 O00255 2/20 0.57
ACR P10323 1/20 0.57
MAPT P10636 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 1/20 0.56
BLM P54132 1/20 0.55
PRSS2 P07478 2/20 0.53
PRSS3 P35030 2/20 0.53
C1S P09871 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3402436 0.98 PARP10 (0.72) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL5330655 0.95 PARP10 (0.66) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL9663679 0.87 PARP10 (0.81) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL9342118 0.86 PRSS1 (0.64) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL7337750 0.85 F12 (0.71) PARP10PRSS1F2F10F12
SCHEMBL23486305 0.85 PARP10 (1.00) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL8205435 0.85 PARP10 (0.78) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL725405 0.84 PARP10 (0.77) PARP10PRSS1TMPRSS15F2PKM
SCHEMBL10492899 0.84 PARP10 (0.53) PARP10PRSS1TMPRSS15F2F10
SCHEMBL10890871 0.84 PRSS1 (0.72) PARP10PRSS1F2KMT2AACR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241054-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20210403420-A1 BENZOATE COMPOUND SCOHIA PHARMA, INC. (JP) 2021-12-30 US disclosed
US-11129825-B2 Polysubunit opioid prodrugs resistant to overdose and abuse ELYSIUM THERAPEUTICS, INC. (US) 2021-09-28 US disclosed
US-20190183884-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2019-06-20 US disclosed
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2018-03-29 US disclosed
US-20170100390-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2017-04-13 US disclosed
EP-2669683-A1 METHOD AND APPARATUS FOR MEASURING PHYSIOLOGICALLY ACTIVE BIOLOGICAL SUBSTANCE Kowa Company Ltd. (JP) 2013-12-04 EP disclosed
US-20130309704-A1 METHOD AND APPARATUS FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE DERIVED FROM ORGANISM KOWA COMPANY, LTD. (JP) 2013-11-21 US disclosed
US-7671057-B2 Therapeutic agent for type II diabetes comprising protease-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2010-03-02 US disclosed
US-20080009537-A1 Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-0151593-B1 ENZYME DERIVATIVES BEECHAM GROUP PLC (GB) 1989-02-22 EP disclosed
US-4604285-A ANTICOAGULANT BEECHAM GROUP P.L.C. (GB) 1986-08-05 US disclosed
EP-0151593-A1 ENZYME DERIVATIVES. BEECHAM GROUP PLC (GB) 1985-08-21 EP disclosed
WO-1985000521-A1 ENZYME DERIVATIVES BEECHAM GROUP P.L.C. (GB) 1985-02-14 WO disclosed
EP-0009879-B1 ENZYME DERIVATIVES FOR USE IN THE TREATMENT OF VENOUS THROMBOSIS, COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION BEECHAM GROUP PLC (GB) 1983-10-12 EP disclosed
EP-0028489-B1 ENZYME DERIVATIVES, AND THEIR PREPARATION BEECHAM GROUP PLC (GB) 1983-10-05 EP disclosed
US-4337244-A COMPRISING A FIBRINOLYTIC ENZYME BLOCKED BY AN END GROUP REMOVABLE BY HYDROLYSIS BEECHAM GROUP LIMITED (GB) 1982-06-29 US disclosed
US-4285932-A Enzyme derivatives for use in the treatment of venous thrombosis BEECHAM GROUP LIMITED (GB) 1981-08-25 US disclosed
EP-0028489-A1 Enzyme derivatives, and their preparation BEECHAM GROUP PLC (GB) 1981-05-13 EP disclosed
EP-0009879-A1 Enzyme derivatives for use in the treatment of venous thrombosis, compositions containing them and their preparation BEECHAM GROUP PLC (GB) 1980-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRD1 PARP10 3466/4885PRSS1 952/4885TMPRSS15 87/4885
US-20210403420-A1 BENZOATE COMPOUND TMPRSS15, DPP4, DPP3 PARP10 4012/4885PRSS1 103/4885TMPRSS15 1/4885
US-20080009537-A1 Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound DPP4, IAPP, DPP7 PARP10 4122/4885PRSS1 25/4885TMPRSS15 21/4885
US-20170100390-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE OPRK1, OPRM1, CYP3A5 PARP10 1884/4885PRSS1 717/4885TMPRSS15 173/4885
US-20230241054-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE OPRK1, OPRM1, CYP3A5 PARP10 1884/4885PRSS1 717/4885TMPRSS15 173/4885
US-11129825-B2 Polysubunit opioid prodrugs resistant to overdose and abuse OPRK1, OPRM1, CYP3A5 PARP10 1884/4885PRSS1 717/4885TMPRSS15 173/4885
US-20190183884-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE OPRK1, OPRM1, CYP3A5 PARP10 1884/4885PRSS1 717/4885TMPRSS15 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.